Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
BXRX - Baudax Bio Inc
$1.48
0.18(13.46%)8:59:56 PM 1/19/2021
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Stock Chart

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/6/2021BXRX
    Baudax Bio to Present at the H.C. Wainwright BioConnect 2021 Conference

    MALVERN, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021. The presentation will be available for on-demand listening beginning Monday, January 11th at 6:00 a.m. Eastern Time and may be ac...

    12/17/2020BXRX
    Baudax Bio Announces $12 Million Offering Priced at a Premium to Market

    MALVERN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it has entered into a definitive agreement with a healthcare-focused institutional investor for the purchase and sale of an aggregate of 10,300,430 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to an aggregate of 10,300,430 shares of common stock a...

    12/8/2020BXRX
    Implied Volatility Surging for Baudax Bio (BXRX) Stock Options

    Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

    12/7/2020BXRX
    Is BXRX A Good Stock To Buy Now?

    In this article we are going to use hedge fund sentiment as a tool and determine whether Baudax Bio, Inc. (NASDAQ:BXRX) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, […]

    11/30/2020BXRX
    Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference

    MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held virtually December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020; meetings may be requested through Piper Sandler. A pre-r...

    11/20/2020BXRX
    Baudax Bio Announces Publication of ANJESO® Network Meta-Analysis in the Peer-Reviewed Journal BMC Anesthesiology

    ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid AnalgesicsMALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the online publication of a Network Meta-Analysis (NMA) for ANJESO (meloxicam) injection in the peer-reviewed medical journal BMC Anesthesiology. ANJESO was recently launched in the U.S. and is indicated ...

    11/19/2020BXRX
    Baudax Bio Announces an additional Orange Book listed patent for ANJESO®

    MALVERN, Pa., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, recently announced the issuance of United States Patent No.10,709,713 (the ‘713 Patent) on July 14, 2020. The ‘713 Patent covers the use of ANJESO® to treat moderate to severe pain, and has been listed in the United States Food and Drug Administration’s (FDA) Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations as it rel...

    11/11/2020BXRX
    Results: Baudax Bio, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

    There's been a notable change in appetite for Baudax Bio, Inc. (NASDAQ:BXRX) shares in the week since its...